KPV(Lys - Pro - Val Tripeptide)

  Product Detail  

1. Core Molecular & Physicochemical Specifications

2. Mechanism of Action

1. CXCR2 Receptor Antagonism: Binds to CXCR2, blocking neutrophil recruitment to inflamed tissues and reducing inflammatory cell infiltration.
2. Inflammatory Pathway Inhibition: Suppresses NF - κB and MAPK signaling, lowering the transcription and secretion of pro - inflammatory cytokines (TNF - α, IL - 6, IL - 8).
3. Antioxidant Regulation: Enhances the activity of superoxide dismutase and glutathione peroxidase, reducing reactive oxygen species (ROS) - induced cellular damage.
4. Wound Healing Promotion: Activates integrin - mediated pathways in fibroblasts and keratinocytes, accelerating wound closure without excessive collagen deposition and scar formation.
5. Antimicrobial Activity: Inhibits the growth of pathogenic bacteria like Staphylococcus aureus and influenza A virus replication in vitro.

3. Biological Functions & Application Fields

3.1 Core Physiological Effects

• Anti - Inflammatory: Reduces skin/intestinal inflammation in preclinical models; alleviates redness, swelling, and itching in inflammatory skin conditions.
• Wound Repair: Promotes keratinocyte/fibroblast migration, shortens wound healing time by ~30% in rodent models, and reduces scarring.
• Antimicrobial: Effective against common skin pathogens; inhibits influenza A virus replication in cell lines and mouse lungs.
• Skin Barrier Enhancement: Strengthens epidermal tight junctions, improving skin resistance to external irritants.

3.2 Application Fields

4. Production & Quality Control

4.1 Manufacturing Processes

1. Solid - Phase Peptide Synthesis (SPPS): Assembles the KPV sequence via Fmoc chemistry; purified by RP - HPLC to reach the target purity.
2. Lyophilization: Produces stable powder; vacuum - sealed with desiccant to prevent moisture absorption and oxidation.
3. Quality Verification: Each batch undergoes mass spectrometry (identity), HPLC (purity), and LAL endotoxin testing before release.

4.2 Quality Testing Standards

5. Administration, Safety & Precautions

5.1 Administration Routes & Dosage

• Topical Use: 0.5% - 1% concentration in creams/serums, applied twice daily for inflammatory skin conditions or wound care.
• Preclinical Injection: Intraperitoneal (IP) injection (1–5 mg/kg/day) in rodent models of systemic inflammation.
• Cell Culture: 1–10 μM for in vitro studies on inflammatory signaling or cell migration.

5.2 Safety Profile

• Low Toxicity: No systemic toxicity in preclinical studies; LD₅₀ > 100 mg/kg in rodents.
• Minimal Side Effects: Transient mild skin irritation (≤2% incidence) at high topical concentrations; no off - target organ damage.
• Contraindications: Hypersensitivity to KPV or peptide components; caution in pregnant/lactating animals (limited data).
• Research/Cosmetic Use Only: Not approved for human clinical systemic administration; widely used in topical skincare products.

5.3 Handling Guidelines

• Storage: Store at - 20°C in a sealed, light - protected container; use within 1 month after reconstitution (store at 4°C).
• Transport: Cold chain transportation (2–8°C) to avoid peptide degradation.
• Preparation: Prepare fresh working solutions before use; discard unused portions after 24 hours.

6. Key Advantages & Limitations

6.1 Advantages

1. Non - Pigmentary: Unlike α - MSH, it does not induce skin pigmentation, suitable for broad skincare applications.
2. Multi - Functional: Combines anti - inflammatory, antimicrobial, and wound - healing effects, addressing multiple skin issues simultaneously.
3. Low Systemic Absorption: Topical use has minimal systemic exposure, reducing safety risks.
4. Easy Production: Short tripeptide structure enables cost - effective synthesis and large - scale production.

6.2 Limitations

1. Preclinical Systemic Use: Limited human clinical data on systemic administration; requires more studies to confirm safety and efficacy.
2. Short Half - Life: Rapid clearance in vivo (plasma half - life ~30–60 minutes); sustained - release formulations needed for systemic therapy.
3. Topical Penetration: Low skin penetration; needs enhancers (e.g., microneedles, liposomes) for deep - tissue efficacy.

 About Us 

  Product Detail  

  Product Detail